


Data Sheet

Product Name:	CFL-137
Cat. No.:	CS-W017605
CAS No.:	708-06-5
Molecular Formula:	C ₁₁ H ₈ O ₂
Molecular Weight:	172.18
Target:	Ras
Pathway:	GPCR/G Protein
Solubility:	10 mM in DMSO



BIOLOGICAL ACTIVITY:

CFL-137 is a potent **KRas^{G12C}** inhibitor. CFL-137 shows an antiproliferative effect. CFL-137 shows anticancer activity. CFL-137 has the potential for the research of lung cancer^[1]. *In Vitro*: CFL-137 (72 h) shows an antiproliferative effect with IC₅₀s of 11.4, 24.2, 24.5, 12.3, 43.3, 44.5, 27.63, 32.4, 46.9, 26.2, 25.0, 10.8, 66.2 μM for H1792, SW1573, MiaPaca2, H358, A549, SW480, PANC-1, LCLC-103H, BxPC3, HCA-7, MRC-5, HUVEC-TERT, CCD-986Sk cells, respectively^[1]. *In Vivo*: CFL-137 (5 mg/kg, 5 treatments; 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments; i.p.) reduces tumor growth in subcutaneous H1792 (KRasG12C mutant) and LCLC-103H (KRasWT) human lung cancer-bearing mice^[1].

Pharmacokinetic Parameters of CFL-137 in NOD-SCID female mice^[1].

PK parameters	CFL-137
C _{max} (ng/mL)	27,366 ± 13,221
T _{max} (h)	0.25
AUC _t (ng/mL*h)	28,307 ± 6375
t _{1/2} (h)	4.0 ± 0.2
V _d (mL)	63.6 ± 13.6
CL (mL/h)	11.0 ± 2.8

NOD-SCID female mice, 15 mg/kg IP^[1].

References:

[1]. Orgován Z, et al. Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency. Eur J Med Chem. 2023 Mar 15;250:115212.

CAIndexNames:

1-Naphthalenecarboxaldehyde, 2-hydroxy-

SMILES:

O=CC1=C2C=CC=CC2=CC=C1O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA